MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaad.2025.11.026

Медицинская библиотека · Journal of the American Academy of Dermatology · 2025

A single-arm phase 2 study of talimogene laherparepvec in patients with lower-risk invasive cutaneous squamous cell cancer.

Stratton Delaney Bake, Adams Anngela Christina, Sundararajan Srinath, Cui Haiyan, Roe Denise J, Curiel-Lewandrowski Clara

СтатьяКлиническое исследование II фазыПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Minimally invasive treatments are increasingly needed for low to intermediate risk cutaneous squamous cell carcinoma (cSCC), particularly in patients with high disease burden.

OBJECTIVE

To evaluate the efficacy and tolerability of intralesional talimogene laherparepvec (TVEC) as a novel immunotherapeutic approach for cSCC in patients seeking non-surgical options.

METHODS

Up to 5 histologically confirmed invasive low to intermediate risk cSCC tumors per patient were treated and referred to as target lesions injected (TLIs). Intralesional TVEC was administered every 2 weeks, up to 4 injections per lesion. Response rate was assessed by subject and individual TLIs.

RESULTS

Eleven patients with 24 cSCC tumors were enrolled. ORR was 100% by patient (11/11) and by tumor (24/24) (95% CI = 76.2%). A confirmed complete response occurred in 90.9% of patients (10/11; 95% CI = 58.7%, 99.8%) involving 23 of 24 tumors. Median duration of response was 212 days (range = 140-236 days). Two years post-treatment, patients showed no recurrence and significantly fewer new primary invasive cSCCs.

LIMITATIONS: Nonrandomized, small sample size, and lesion site exclusions.

CONCLUSION

Intralesional TVEC demonstrated promising efficacy and tolerability as a minimally invasive treatment for low to intermediate risk cSCC with potential to reduce subsequent incidence rates.

Для цитирования: Stratton Delaney Bake, Adams Anngela Christina, Sundararajan Srinath, Cui Haiyan, Roe Denise J, Curiel-Lewandrowski Clara. A single-arm phase 2 study of talimogene laherparepvec in patients with lower-risk invasive cutaneous squamous cell cancer.. Journal of the American Academy of Dermatology. 2025. DOI: 10.1016/j.jaad.2025.11.026.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.